FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2272532372> ?p ?o ?g. }

• W2272532372 endingPage "21166" @default.
• W2272532372 startingPage "21166" @default.
• W2272532372 abstract "21166 Background: A cancer vaccine composed of MUC1 loaded DCs was effective at inducing tumor rejection in MUC1 transgenic mice. We present data from a phase IB clinical trial of the same vaccine in patients with pancreatic cancer. Preliminary analysis of this trial was reported at ASCO 2004,# 2578. Our current studies based on the results of this trial explore the importance of anti-MUC1 immunity in patients with early breast cancer, aiming to create a strong rationale for boosting these responses with vaccination in adjuvant settings. Data from both studies will be presented. Methods: The objectives of the vaccine trial were to evaluate toxicity of the vaccine, its ability to boost immunity and clinical outcome. Patients received autologous DC loaded with MUC1 100mer peptide every 3 weeks for a total of 3 doses and a booster dose 6 months later. Blood samples were obtained prior to each dose and at various times post vaccination. For the current study, 100 preoperative/pretreatment peripheral blood samples have been collected prospectively from patients with early breast cancer. Multiple immune parameters are being assessed in each group. Results: Data from extensive immune response analyses of the pancreatic cancer vaccine will be presented in detail at AACR 2007, and summarized here to provide the basis and comparison for our ongoing studies in early breast cancer. 4/12 patients in the vaccine study are alive without recurrence at three years. Even though effector and regulatory T cell responses were detected in several patients, none could be correlated with long-term survival. Several patients had anti-MUC1 antibody responses that remained stable following vaccination, which also did not correlate with survival. Ongoing studies in early breast cancer are assessing the potential differences in the quality of anti-MUC1 responses between early and late stage disease. Conclusions: In the setting of advanced disease, such as pancreatic cancer, the vaccine appears to have an effect on keeping regulatory T cells low and cellular and humoral immunity stable, without causing any significant toxicity. Ongoing studies in early breast cancer are aiming to define the immune parameters that might predict increased survival. No significant financial relationships to disclose." @default.
• W2272532372 created "2016-06-24" @default.
• W2272532372 creator A5024170610 @default.
• W2272532372 creator A5024545307 @default.
• W2272532372 creator A5033786876 @default.
• W2272532372 creator A5044108002 @default.
• W2272532372 creator A5060812600 @default.
• W2272532372 creator A5060904857 @default.
• W2272532372 date "2007-06-20" @default.
• W2272532372 modified "2023-09-30" @default.
• W2272532372 title "Immunity to MUC1 in pancreatic and breast cancer" @default.
• W2272532372 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.21166" @default.
• W2272532372 hasPublicationYear "2007" @default.
• W2272532372 type Work @default.
• W2272532372 sameAs 2272532372 @default.
• W2272532372 citedByCount "0" @default.
• W2272532372 crossrefType "journal-article" @default.
• W2272532372 hasAuthorship W2272532372A5024170610 @default.
• W2272532372 hasAuthorship W2272532372A5024545307 @default.
• W2272532372 hasAuthorship W2272532372A5033786876 @default.
• W2272532372 hasAuthorship W2272532372A5044108002 @default.
• W2272532372 hasAuthorship W2272532372A5060812600 @default.
• W2272532372 hasAuthorship W2272532372A5060904857 @default.
• W2272532372 hasConcept C121608353 @default.
• W2272532372 hasConcept C126322002 @default.
• W2272532372 hasConcept C143998085 @default.
• W2272532372 hasConcept C203014093 @default.
• W2272532372 hasConcept C22070199 @default.
• W2272532372 hasConcept C2777701055 @default.
• W2272532372 hasConcept C2777863537 @default.
• W2272532372 hasConcept C2778378633 @default.
• W2272532372 hasConcept C2779341262 @default.
• W2272532372 hasConcept C2780210213 @default.
• W2272532372 hasConcept C530470458 @default.
• W2272532372 hasConcept C535046627 @default.
• W2272532372 hasConcept C71924100 @default.
• W2272532372 hasConcept C8891405 @default.
• W2272532372 hasConceptScore W2272532372C121608353 @default.
• W2272532372 hasConceptScore W2272532372C126322002 @default.
• W2272532372 hasConceptScore W2272532372C143998085 @default.
• W2272532372 hasConceptScore W2272532372C203014093 @default.
• W2272532372 hasConceptScore W2272532372C22070199 @default.
• W2272532372 hasConceptScore W2272532372C2777701055 @default.
• W2272532372 hasConceptScore W2272532372C2777863537 @default.
• W2272532372 hasConceptScore W2272532372C2778378633 @default.
• W2272532372 hasConceptScore W2272532372C2779341262 @default.
• W2272532372 hasConceptScore W2272532372C2780210213 @default.
• W2272532372 hasConceptScore W2272532372C530470458 @default.
• W2272532372 hasConceptScore W2272532372C535046627 @default.
• W2272532372 hasConceptScore W2272532372C71924100 @default.
• W2272532372 hasConceptScore W2272532372C8891405 @default.
• W2272532372 hasIssue "18_suppl" @default.
• W2272532372 hasLocation W22725323721 @default.
• W2272532372 hasOpenAccess W2272532372 @default.
• W2272532372 hasPrimaryLocation W22725323721 @default.
• W2272532372 hasRelatedWork W155301942 @default.
• W2272532372 hasRelatedWork W2019574320 @default.
• W2272532372 hasRelatedWork W2028341220 @default.
• W2272532372 hasRelatedWork W2055086849 @default.
• W2272532372 hasRelatedWork W2063213049 @default.
• W2272532372 hasRelatedWork W2090324576 @default.
• W2272532372 hasRelatedWork W2171475287 @default.
• W2272532372 hasRelatedWork W2439906857 @default.
• W2272532372 hasRelatedWork W4206914007 @default.
• W2272532372 hasRelatedWork W4221063257 @default.
• W2272532372 hasVolume "25" @default.
• W2272532372 isParatext "false" @default.
• W2272532372 isRetracted "false" @default.
• W2272532372 magId "2272532372" @default.
• W2272532372 workType "article" @default.